Tagged with P

USA David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation of the Marijuana Tax Act of 1937 and continue to persist to this day.   With all this history, why…

Egypt Dr Wafik Bardissi, chairman and CEO of Minapharm, the only company to offer biosimilars in Egypt, highlights how the company has successfully developed biotech know-how by partnering with and acquiring German companies. He also emphasizes the need for more local manufacturing and improving biosimilar infrastructure in Egypt.   As Minapharm…

Spain Jaime Vives, managing director of Roche Diagnostics in Spain, discusses the digital solutions Roche Diagnostics is trying to roll out in Spain, the challenges involved, and the potential implications of digitalising healthcare   The first step into digitalization is to convince our customers to standardise their systems and the way…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.   The smooth operation of the drug distribution chain in Algeria is compromised by its multiplicity of actors – from…

France Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health professionals, patients, the pharma industry, and healthcare systems. As a newly implemented leader tasked with growing the affiliate and developing…

China Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders…

France Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging markets strategy, while reaffirming Pierre Fabre’s commitment to France’s healthcare innovation ecosystem. As illustrated by the group’s new motto ‘Taking…

Opinion Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring a more comprehensive rollout of these models around the globe.   We’re looking forward to being one customer of many…

Opinion Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars.   Savings have totaled…

Taiwan Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique positioning of nanomedicine within oncology and Taiwan’s role as an active participant in the global fight against cancer.   PharmaEngine…

Spain Francisco Coll, CEO of Quinton, explains the background behind the company’s seawater therapies and how they are expanding this originally French brand internationally. Coll also sheds light on his strategy to leverage social media in order to market and distribute Quinton’s leading products.   The seawater must be collected from…

Egypt Dr Mohamed Mabrouk, CEO of Pharmed Healthcare, highlights how the company has evolved from only offering Hepatitis C treatment to having 112 products in the pipeline today. He also emphasises the importance of local companies for the government’s 100 Million Seha campaign, while outlining Pharmed’s future strategy including commercial partnerships…